On December 29, 2023, Brady Granier submitted his letter of resignation as President of BioCorRx Inc. effective January 31, 2024. Mr. Granier will continue to serve as a member of the Company?s board of directors. Mr. Granier's resignation did not arise as a result of any disagreement with the Company nor BioCorRx Pharmaceuticals.

On January 5, 2024, in light of the Granier Resignation, the Board appointed Louis Lucido as Interim President of the Company, effective immediately through January 31, 2024, and transitioning to President on February 1, 2024. Mr. Lucido will remain a member of the Board. Mr. Lucido, 75, was formerly the Senior Advisor and Chief Operating Officer of DoubleLine Group, LP.

He was one of the five founding partners of DoubleLine in December of 2009. He was previously at TCW as a Group Managing Director. Prior to joining TCW in 2001, Mr. Lucido was the Chief Investment Officer for Delphi Financial Group (?DFG?) and on several subsidiary Boards.

Before DFG, he was the Chief Operating Officer, MD, and Secretary for Hyperion Capital Management & was also a member of the Resolution Trust Advisory Committee. From 2013-2018, he served as a member of the Board of Directors of CASA of Los Angeles and Chair. Current member of the board for National CASA since 2018.

Formerly served on the Boards of Junior Achievement, Southern California, 826LA, and the Lupus Research Alliance (formerly the Alliance for Lupus Research). Mr. Lucido received his MBA in Management and Finance from New York University and was a member of the Dean?s Advisory Board of the N.Y.U. Stern School of Business. Mr. Lucido has been a Director of BioCorRx Inc. since March 1, 2019.